Table 2.

HAE-specific medications used during study period (2006–2014) in 631 patients with HAE in the US^a

HAE Medications	N (%) of Patients (N = 631)
Icatibant and/or ecallantide only	197 (31.2)
Any use C1-INH(IV)	434 (68.8)
C1-INH(IV)/Cinrzye	110 (17.4)
C1-INH(IV)/Cinryze + icatibant/ecallantide	97 (15.4)
C1-INH(IV)/Berinert	87 (13.8)
C1-INH(IV)/Berinert + icatibant/ecallantide	53 (8.4)
C1-INH(IV)/Cinryze + C1-INH(IV)/Berinert + icatibant/ ecallantide	49 (7.8)
C1-INH(IV)/Cinryze + C1-INH(IV)/Berinert	38 (6.0)

HAE hereditary angioedema

^aAll HAE-specific medications recorded during study period